Teva Expects To Benefit From Consolidation Driven By "Authorized" Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic firms with smaller pipelines will feel pressure from authorized generics, CEO Makov says. Teva will not pursue a Mylan/King type of acquisition to boost its brand business because "we are doing very well in generics," the exec says.